Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1980 Mar;39(3):551–561.

Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.

W E Brandeis, C Tan, Y Wang, R A Good, N K Day
PMCID: PMC1538137  PMID: 7379328

Abstract

Serum levels of circulating immune complexes (CIC) assayed by the Raji cell radioimmunoassay, total haemolytic complement (TCH50), Clq and C3 were correlated with clinical stage, histological type, age, sex and treatment of eighty-six children with Hodgkin's disease over a period of 4 years. Most significant findings were the changes of levels of CIC, TCH50, Clq and C3 during disease activity and following treatment. Significant perturbations were also seen in association with relapse. Levels of C and CIC were significantly elevated (P less than 0.001) at the time of diagnosis prior to splenectomy and/or any treatment. In the group before treatment, 81 percent of CIC levels were above 16 micrograms/ml with a maximum value of 1120 micrograms/ml. During treatment 33 percent were still above normal with a maximum of 320 micrograms/ml. Within 1 year after cessation of treatment, 37 percent also remained above normal levels with a maximum of 240 micrograms/ml. At relapse prior to treatment, 63 percent were again elevated with a maximum of 1280 micrograms/ml. The most significant difference on TCH50 levels relates to treatment periods. Sera of patients with active disease who are previously untreated show elevation of TCH50 levels (P less than 0.001) (average 127 CH50 mu/ml. During and after treatment eht TCH50 levels drop to 96 and 102 CH50 mu/ml, as compared to normal control of 100 CH50 mu/ml. In sera of patients at the first, second or third relapse, the combined TCH50 levels are significantly different from controls and across treatment periods (P less than 0.005).

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amlot P. L., Pussell B., Slaney J. M., Williams B. D. Correlation between immune complexes and prognostic factors in Hodgkin's disease. Clin Exp Immunol. 1978 Feb;31(2):166–173. [PMC free article] [PubMed] [Google Scholar]
  2. Amlot P. L., Slaney J. M., Williams B. D. Circulating immune complexes and symptoms in Hodgkin's disease. Lancet. 1976 Feb 28;1(7957):449–451. doi: 10.1016/s0140-6736(76)91475-6. [DOI] [PubMed] [Google Scholar]
  3. Balzola F., Berruti C., Segre E. Il comportamento del complemento e delle sue frazioni nelle emopatie sistemiche. Cancro. 1964;17(6):520–530. [PubMed] [Google Scholar]
  4. Brandeis W. E., Helson L., Wang Y., Good R. A., Day N. K. Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease. J Clin Invest. 1978 Dec;62(6):1201–1209. doi: 10.1172/JCI109240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  6. Congdon C. C. The destructive effect of radiation on lymphatic tissue. Cancer Res. 1966 Jun;26(6):1211–1220. [PubMed] [Google Scholar]
  7. Day N. K., Winfield J. B., Gee T., Winchester R., Teshima H., Kunkel H. G. Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1976 Nov;26(2):189–195. [PMC free article] [PubMed] [Google Scholar]
  8. Heier H. E., Carpentier N., Lange G., Lambert P. H., Godal T. Circulating immune complexes in patients with malignant lymphomas and solid tumors. Int J Cancer. 1977 Dec 15;20(6):887–894. doi: 10.1002/ijc.2910200611. [DOI] [PubMed] [Google Scholar]
  9. Irunberry J., Colonna P. Intérêt de l'immuno-electrophorèse des protéines sériques au cours de la maladie de Hodgkin. Presse Med. 1970 Jan 24;78(4):187–188. [PubMed] [Google Scholar]
  10. Kávai M., Berényi E., Pálkovi E., Szegedi G. Letter: Immune complexes in Hodgkin's disease. Lancet. 1976 Jun 5;1(7971):1249–1249. doi: 10.1016/s0140-6736(76)92209-1. [DOI] [PubMed] [Google Scholar]
  11. LIBANSKY J., JEZKOVA Z. INVESTIGATIONS OF THE IMMUNOLOGICAL REACTIVITY IN HAEMOBLASTOSES. II. BLOOD COMPLEMENT VALUES IN LEUKAEMIA, MALIGNANT LYMPHOMA, AND MYELOMA. Neoplasma. 1963;10:605–619. [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Lichtenfeld J. L., Wiernik P. H., Mardiney M. R., Jr, Zarco R. M. Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease, and sarcoma. Cancer Res. 1976 Oct;36(10):3678–3680. [PubMed] [Google Scholar]
  14. Long J. C., Hall C. L., Brown C. A., Stamatos C., Weitzman S. A., Carey K. Binding of soluble immune complexes in serum of patients with Hodgkin's disease to tissue cultures derived from the tumor. N Engl J Med. 1977 Aug 11;297(6):295–299. doi: 10.1056/NEJM197708112970602. [DOI] [PubMed] [Google Scholar]
  15. Maness P. F., Orengo A. Serum complement levels in patients with digestive tract carcinomas and other neoplastic diseases. Oncology. 1977;34(2):87–89. doi: 10.1159/000225191. [DOI] [PubMed] [Google Scholar]
  16. McConahey P. J., Dixon F. J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. doi: 10.1159/000229699. [DOI] [PubMed] [Google Scholar]
  17. McKenzie D., Colsky J., Hetrick D. L. Complement reactivity of cancer patients: measurements by immune hemolysis and immune adherence. Cancer Res. 1967 Dec;27(12):2386–2394. [PubMed] [Google Scholar]
  18. ROTTINO A., LEVY A. L. Behavior of total serum complement in Hodgkin's disease and other malignant lymphomas. Blood. 1959 Mar;14(3):246–254. [PubMed] [Google Scholar]
  19. SCHIER W. W., ROTH A., OSTROFF G., SCHRIFT M. H. Hodgkin's disease and immunity. Am J Med. 1956 Jan;20(1):94–99. doi: 10.1016/0002-9343(56)90176-0. [DOI] [PubMed] [Google Scholar]
  20. SOUTHAM C. M., GOLDSMITH Y. Effect of nitrogen mustard on serum complement in vitro and in patients with neoplastic disease. Proc Soc Exp Biol Med. 1951 Mar;76(3):430–432. doi: 10.3181/00379727-76-18513. [DOI] [PubMed] [Google Scholar]
  21. Southam C. M., Siegel A. H. Serum levels of second component of complement in cancer patients. J Immunol. 1966 Sep;97(3):331–337. [PubMed] [Google Scholar]
  22. Tan C. T., de Sousa M., Tan R., Hansen J. A., Good R. A. In vitro responses of peripheral blood and spleen lymphoid cells to mitogens and antigens in childhood Hodgkin's disease. Cancer Res. 1978 Apr;38(4):886–893. [PubMed] [Google Scholar]
  23. Tan C., D'angio G. J., Exelby P. R., Lieberman P. H., Watson R. C., Cham W. C., Murphy M. L. The changing management of childhood Hodgkin's disease. Cancer. 1975 Mar;35(3):808–816. doi: 10.1002/1097-0142(197503)35:3<808::aid-cncr2820350337>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  24. Theofilopoulos A. N., Wilson C. B., Dixon F. J. The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest. 1976 Jan;57(1):169–182. doi: 10.1172/JCI108257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. WOOD H. F., DIAMOND R. D., CRAVER L. F., PADER E., EISTER S. K. Determination of C-reactive protein in the blood of patients with Hodgkin's disease. Ann Intern Med. 1958 Apr;48(4):823–833. doi: 10.7326/0003-4819-48-4-823. [DOI] [PubMed] [Google Scholar]
  26. Wagener D. J., Haanen C. Total serum haemolytic complement activity, erythrocyte sedimentation rate and plasma fibrinogen as indicators of the stage in Hodgkin's disease. Eur J Clin Invest. 1977 Aug;7(4):289–294. doi: 10.1111/j.1365-2362.1977.tb01607.x. [DOI] [PubMed] [Google Scholar]
  27. Weitzman S. A., Aisenberg A. C., Siber G. R., Smith D. H. Impaired humoral immunity in treated Hodgkin's disease. N Engl J Med. 1977 Aug 4;297(5):245–248. doi: 10.1056/NEJM197708042970504. [DOI] [PubMed] [Google Scholar]
  28. de Sousa M., Tan C. T., Siegal F. P., Filippa D. A., Tan R., Good R. A. Immunologic parameters in childhood Hodgkin's disease II. T and B lymphocytes in the peripheral blood of normal children and in the spleen and peripheral blood of children with Hodgkin's disease. Pediatr Res. 1978 Feb;12(2):143–147. doi: 10.1203/00006450-197802000-00016. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES